10. The use according to any one of claims 1 to 9, wherein the compound(s) of said medicament increase(s) or stimulate(s) glucose uptake in adipocytes and/or muscular cells in said mammalian subject.

11. The use according to any one of claims 1 to 9, wherein the compound(s) of said medicament decrease(s) apoptosis of pancreatic beta cells in said mammalian subject.

12. The use according to any one of claims 1 to 8, wherein the compound(s) of said medicament decrease(s) insulin resistance in said mammalian subject.

13. The use according to claims 1, 9 and 12, wherein the subject is suffering from type 2 diabetes.

14. The use according to any one of the preceding claims, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

15. The use according to claims 2 to 14, wherein the compounds in said medicament are formulated or administered together, separately or sequentially.

16. The use according to any one of the preceding claims, wherein said medicament is administered repeatedly to the subject.

17. A composition comprising at least one of the following combinations of compounds:

- ~~ifenprodil and acamprosate,~~
- ~~ifenprodil and baclofen,~~
- ifenprodil and nicergoline,
- ifenprodil and fenspiride,
- ifenprodil and torasemide,
- ifenprodil and triamterene,
- ifenprodil and tolfenamic acid,
- ifenprodil and metformin
- ifenprodil and acamprosate and metformin,